120mg 100ct
Sotalol Hydrochloride Tablet
Product Images NDC 42806-121
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Sotalol Hydrochloride (NDC 42806-121). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Epic Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
160mg 100ct
This is a medication label for Sotalol Hydrochloride USP tablets containing 160 mg each. The usual dosage information is provided on the accompanying material. The tablets should be dispensed in a light-resistant container and kept at controlled room temperature. The medication should be kept out of reach of children. The label includes lot and expiration information, manufacturer information and the prescription information.*
80mg 100ct
This is a prescription drug with usual dosage information given in the accompanying literature. It contains Sotalol Hydrochloride in 80mg strength and is manufactured by Epic Pharma LLC. It is recommended to store the drug in a tightly closed and light-resistant container at room temperature. The drug should be dispensed with a resistant closure as required. The package comes with a patient information leaflet and should be kept out of the reach of children.*
Age Graph
Figure-1-study-1 (Figure 1 Study 1)
The text represents a graph showing the Recurrence-Free Survival rates for different doses of Sotalol Hydrochloride Tablets (AF) against the Placebo, measured over a period of 360 days. The graph also shows the P-values with respect to the Log-Rank test for each dosage, indicating the statistical significance of the results.*
Figure-2-study-2 (Figure 2 Study 2)
This is a graph representing the recurrence-free survival of patients who were administered Sotalol Hydrochloride Tablets (AF) versus Placebo. The X-axis represents the time in days and the Y-axis represents the probability of recurrence-free survival. The graph shows a comparison of the two treatments over a period of 180 days. The study seems to have ended after the 180-day duration.*
Steps Diagram
The text describes guidelines for administering sotalol hydrochloride tablets for patients with certain baseline QT values and creatine clearance levels. The patient should be on telemetry and have their QT levels monitored before and after each dose. The dosage of sotalol hydrochloride tablets (AF) depends on the patient's Cler levels. If QT levels exceed a certain threshold, the medication should be discontinued. Alternatively, the dosage can be increased with careful monitoring during the hospitalization period.*
Structure Formula
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
